- Home
- JANX vs NAD Comparison
JANX vs NAD Comparison
Compare JANX & NAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JANX | NAD |
|---|---|---|
| Founded | 2017 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 840.4M | 2.7B |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | JANX | NAD |
|---|---|---|
| Price | $13.36 | $11.74 |
| Analyst Decision | Buy | |
| Analyst Count | 13 | 0 |
| Target Price | ★ $47.00 | N/A |
| AVG Volume (30 Days) | ★ 862.8K | 614.0K |
| Earning Date | 05-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.35% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.12 | $11.04 |
| 52 Week High | $35.34 | $12.31 |
Technical Indicators
Market Signals| Indicator | JANX | NAD |
|---|---|---|
| Relative Strength Index (RSI) | 35.27 | 47.25 |
| Support Level | $13.15 | $11.66 |
| Resistance Level | $14.64 | $11.94 |
| Average True Range (ATR) | 0.48 | 0.10 |
| MACD | -0.10 | 0.01 |
| Stochastic Oscillator | 5.26 | 59.63 |
Price Performance
Historical ComparisonAbout JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
About NAD Nuveen Quality Municipal Income Fund
Nuveen Quality Municipal Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide current income exempted from regular federal income tax by investing in tax-exempt municipal securities that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.